VEGFA and neoplasm: Preliminary evidence has indeed demonstrated that anti-angiogenesis, especially targeting VEGF, might reverse the immunosuppression in tumor microenvironment of RCC, potentially promoting the efficacy of subsequent immunotherapy (48, 49).